26
|
Ducassou A, David I, Delannes M, Chevreau C, Sibaud V. Radiosensibilisation induite par le vémurafénib. Cancer Radiother 2013; 17:304-7. [DOI: 10.1016/j.canrad.2013.04.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2013] [Revised: 04/10/2013] [Accepted: 04/12/2013] [Indexed: 11/16/2022]
|
27
|
Blanchard P, Delannes M, Haie-Meder C. Curiethérapie des cancers de la verge. Cancer Radiother 2013; 17:140-2. [DOI: 10.1016/j.canrad.2012.12.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2012] [Accepted: 12/13/2012] [Indexed: 11/24/2022]
|
28
|
Cosset JM, Hannoun-Lévi JM, Peiffert D, Delannes M, Pommier P, Pierrat N, Nickers P, Thomas L, Chauveinc L. Curiethérapie du cancer prostatique par implants permanents : le point en 2013. Cancer Radiother 2013; 17:111-7. [DOI: 10.1016/j.canrad.2013.01.009] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2013] [Accepted: 01/29/2013] [Indexed: 10/27/2022]
|
29
|
Delannes M, Thomas L, Brun T, David I, Ducassou A. Curiethérapie des sarcomes des tissus mous des membres. Cancer Radiother 2013; 17:151-4. [DOI: 10.1016/j.canrad.2012.12.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2012] [Accepted: 12/19/2012] [Indexed: 10/27/2022]
|
30
|
Delannes M, Rio E, Mirabel X, Brun T, Ducassou A, David I. Curiethérapie des carcinomes cutanés et de la lèvre. Cancer Radiother 2013; 17:136-9. [DOI: 10.1016/j.canrad.2013.02.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2013] [Accepted: 02/13/2013] [Indexed: 11/27/2022]
|
31
|
Huyghe E, Delaunay B, Njomnang Soh P, Delannes M, Walschaerts M, Delavierre D, Soulie M, Bachaud JM. Proposal for a predictive model of erectile function after permanent 125I prostate brachytherapy for localized prostate cancer. Int J Impot Res 2013; 25:121-6. [DOI: 10.1038/ijir.2013.3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2012] [Revised: 11/23/2012] [Accepted: 01/16/2013] [Indexed: 11/09/2022]
|
32
|
Huyghe E, Genebes C, Filleron T, Soulie M, Jonca F, Belossi P, Thoulouzan M, Delaunay B, Ducassou A, Aziza R, Bonnet J, Brun T, Delannes M, Bachaud JM. Résultats carcinologiques et fonctionnels (urinaires et digestifs) obtenus chez 748 patients consécutifs traités par implant permanent de grains d’iode125 pour un adénocarcinome prostatique. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Bachaud JM, Genebes C, Filleron T, Soulie M, Jonca F, Aziza R, Bonnet J, Delannes M, Belossi P, Thoulouzan M, Delaunay B, Ducassou A, Brun T, Huyghe E. Curiethérapie prostatique par implant permanent de grains d’iode125 : comparaison de trois techniques successives d’implantation. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Delannes M, Maire JP, Sabatier J, Thillays F. Radiothérapie stéréotaxique des méningiomes intracrâniens. Cancer Radiother 2012; 16 Suppl:S79-89. [DOI: 10.1016/j.canrad.2011.07.249] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2011] [Accepted: 07/29/2011] [Indexed: 10/28/2022]
|
35
|
Camilleri J, Laprie A, Kerjean P, Kerjean J, Gros-Dagnac H, Moyal E, Delannes M, Ken S, Franceries X. EP-1242 OPTIMIZATION OF DOSE PRESCRIPTION IN SKIN CARCINOMAS RADIOTHERAPY: HOW TO USE BOLUSES EFFECTIVELY? Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71575-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Delannes M. 103 WHAT ARE THE BEST INDICATIONS FOR BRACHYTHERAPY IN NON-MELANOMA SKIN CANCERS? Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)72070-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
37
|
Pommier P, Delannes M, Thomas L, Servagi-Vernat S, Crehange G, Williaume D, Llacer C, Untereiner M, Bajard A. PO-211 PROSTATE BRACHYTHERAPY USING AN AUTOMATIC SEED AFTERLOADER: PRELIMINARY EXPERIENCE IN 1037 PATIENTS. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)72177-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
38
|
Ken S, Vieillevigne L, Franceries X, Supper C, Lotterie J, Filleron T, Lubrano V, Berry I, Cassol E, Delannes M, Celsis P, Moyal ECJ, Laprie A. 209 MR SPECTROSCOPY IMAGING (MRSI) FOR GLIOBLASTOMA DOSE PAINTING WITH INTENSITY MODULATED RADIATION THERAPY COMPRISING SIMULTANEOUS INTEGRATED BOOST ON SPECIFIC TARGETS. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70179-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Mboup AK, Ken S, Franceries X, Deviers A, Delannes M, Lotterie JA, Berry I, Celsis P, Moyal Cohen-Jonathan É, Laprie A. Imagerie de spectrométrie par résonance magnétique du glioblastome : étude longitudinale de nouveaux indices métaboliques prédictifs de la rechute. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Camilleri J, Laprie A, Sors A, Kerjean P, Kerjean JC, Gros-Dagnac H, Moyal É, Delannes M, Franceries X. Doit-on changer la technique d’utilisation des bolus en radiothérapie des cancers cutanés ? Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
41
|
Delaunay B, Delannes M, Salloum A, Delavierre D, Wagner F, Jonca F, Thoulouzan M, Plante P, Bachaud JM, Soulie M, Huyghe E. [Orgasm after curietherapy with permanent iodine-125 radioimplants for localized prostate cancer]. Prog Urol 2011; 21:932-9. [PMID: 22118358 DOI: 10.1016/j.purol.2011.05.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2010] [Revised: 12/03/2010] [Accepted: 05/11/2011] [Indexed: 01/23/2023]
Abstract
OBJECTIVES Orgasm is a domain of male sexuality that remains underreported in literature. Our aim was to realize the first detailed analysis of orgasm in patients treated by 125 I permanent prostate brachytherapy for localized prostate cancer. PATIENTS AND METHODS In a series of 270 sexually active men treated by prostate brachytherapy (125I permanent implantation), 241 (89%), mean age of 65 (43-80), participated in a mailed survey about sexual function after a mean time of 36 months (9-70). Erectile and ejaculatory functions and orgasm were explored using a mailed questionnaire. Two questions focused on orgasm. The first was about quality of orgasm (fast/intense/late, difficult/weak/absent) and the second about the presence of painful orgasm and its frequency (always/sometimes/often). RESULTS After prostate brachytherapy, 81.3% of sexually active men conserved ejaculation and 90% orgasm. There was a significant deterioration of the quality of orgasm (P=0.0001). More than 50% of the patients had an altered orgasm (weak, difficult, absent) after brachytherapy, vs 16% before implantation (P=0.001). Men with a diminished ejaculation volume often had a weak/difficult orgasm (P=0.007). Neoadjuvant hormonal therapy did not seem to impact the quality of orgasm or the frequency of painful ejaculation. Patients who had an IIEF-5 score higher than 12 had frequently intense orgasm (26.7% vs 2.7%; P<0.001) after brachytherapy. Sixty patients (30.3%) experienced often/sometimes painful ejaculation 12.9% (n=31) before implantation (P=0.0001). CONCLUSION Most of the patients treated by prostate brachytherapy conserved orgasm after treatment. However, most of the patients described a deterioration of the quality of orgasm.
Collapse
|
42
|
Laprie A, Vieillevigne L, Ken S, Supper C, Thomas F, Franceries X, Simon L, Hangard G, Lotterie J, Michel R, Delannes M, Berry I, Pierre C, Moyal-Cohen-Jonathan E. 333 oral GLIOBLASTOMA DOSE PAINTING WITH IMRT SIMULTANEOUS INTEGRATED BOOST GUIDED BY MR SPECTROSCOPY. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70455-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Martínez A, Filleron T, Vitse L, Querleu D, Mery E, Balague G, Delannes M, Soulie M, Pomel C, Ferron G. Laparoscopic pelvic exenteration for gynaecological malignancy: is there any advantage? Gynecol Oncol 2011; 120:374-9. [PMID: 21215437 DOI: 10.1016/j.ygyno.2010.11.032] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2010] [Revised: 11/19/2010] [Accepted: 11/22/2010] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Pelvic exenteration (PE) remains one of the most mutilating surgical procedures with important postoperative morbidity. Laparoscopic approach has emerged in an attempt to reduce postoperative complications. The aim of the present study was to compare outcomes between laparoscopic pelvic exenteration combined with a vaginal or perineal approach, versus classical approach. METHODS A cohort study was performed by identifying patients who underwent laparoscopic pelvic exenteration, and retrospectively comparing data with open cases from the same period of time, from 2000 to 2008. RESULTS Fourteen patients underwent laparoscopic PE and 29 patients underwent an open exenterative procedure. All patients except one (97.6%) had received prior radiotherapy. Eighteen patients (41.9%) underwent total PE, 17 anterior PE (39.5%), and 8 posterior PE (18.6%). Urinary diversion (UD) technique consisted of 24 Miami pouch (68.6%), 9 Bricker diversion (25.7%), 1 Kock pouch (2.9%), and 1 ureterostomy (2.9%). Most frequent postoperative complications were related to the urinary diversion (45%) and bowel reconstruction (27.9%). Median estimated blood loss for the laparoscopy and laparotomy group was 400 ml (range 200-700 ml) and 875 ml (range 200-1600 ml), respectively. Transfusion rate was also significantly higher in the laparotomy group. Operative time, margin status, length of hospital stay, operative and postoperative morbidity, and disease and overall survival were not significantly different between both groups. CONCLUSIONS Laparoscopic PE is feasible with curative intent to selected patients. Potential postoperative advantages of laparoscopic approach when compared to classical approach, oncological safety of the procedure, and QOL considerations need to be further investigated.
Collapse
|
44
|
Supper C, Vieillevigne L, Franceries X, Ken S, Simon L, Rives M, Moyal É, Delannes M, Noël A, Laprie A. Optimisation de la balistique en modulation d’intensité avec intégration d’un boost concomitant pour la radiothérapie des glioblastomes. Cancer Radiother 2010. [DOI: 10.1016/j.canrad.2010.07.505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Ken S, Franceries X, Lotterie JA, Lubrano V, Catalaa I, Vieillevigne L, Berry I, Cassol E, Delannes M, Celsis P, Moyal Cohen-Jonathan E, Laprie A. R102: La spectrométrie par résonance magnétique 3D intégrée comme nouveaux volumes-cibles pour la radiothérapie des glioblastomes. Bull Cancer 2010. [DOI: 10.1016/s0007-4551(15)31021-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
46
|
Remonnay R, Morelle M, Pommier P, Haie-Meder C, Quetin P, Kerr C, Delannes M, Castelain B, Peignaux K, Kirova Y, Romestaing P, Williaume D, Krzisch C, Thomas L, Lang P, Baron M, Cussac A, Lesaunier F, Maillard S, Barillot I, Charra-Brunaud C, Carrère MO, Peiffert D. Évaluation économique de la curiethérapie de débit pulsé gynécologique (PDR) avec optimisation de la dose pour les cancers du col utérin. Cancer Radiother 2010; 14:161-8. [DOI: 10.1016/j.canrad.2009.11.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2008] [Revised: 06/18/2009] [Accepted: 11/19/2009] [Indexed: 10/19/2022]
|
47
|
Vaysse C, Pautier P, Filleron T, Maisongrosse V, Lavoué V, Rodier J, Brunaud C, Guizard A, Peignaux-Casasnovas K, Delannes M. A retrospective analysis of nonmetastatic primary mucosal melanoma of the vagina: Clinical practice evaluation in different French institutes. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e15500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Fabbro M, Gladieff L, Guichard F, El Demery M, Dalenc F, Kerr C, Delannes M, Paraiso D, Pujade-Lauraine E, Kurtz JE. Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial. Gynecol Oncol 2010; 117:276-80. [PMID: 20226502 DOI: 10.1016/j.ygyno.2009.12.027] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2009] [Revised: 12/16/2009] [Accepted: 12/21/2009] [Indexed: 10/19/2022]
Abstract
PURPOSE To define the recommended dose of the association of weekly irinotecan (Iri) and cisplatin (CP) with pelvic radiotherapy in Locally Advanced Cervical Cancer. PATIENTS AND METHODS Stage IB2-IV cervix cancer patients were treated with escalating doses of Iri starting from 30 mg/m(2) and a fixed dose of CP at 20 mg/m(2), both weekly concomitantly with a 45-Gy pelvic irradiation. RESULTS Fifteen patients entered the study, 6 at level 1 (Iri 30 mg/m(2)), 3 at level 2 (Iri 40 mg/m(2)) and 6 at intermediate dose (Iri 35 mg/m(2)). Median age was 47 years (34-72), FIGO stage IB (n=1), IIB (n=7), III (n=6), IVA (n=1). The recommended dose was weekly Iri 35 mg/m(2) and CP 20 mg/m(2). Dose limiting toxicities (grades 3-4) were diarrhea, abdominal pain, febrile neutropenia and fatigue. CONCLUSION In cervix cancer patients, radiosensitization with weekly cisplatin and irinotecan is feasible, and the recommended doses are cisplatin 20 mg/m(2)/week and irinotecan 35 mg/m(2)/week for future phase II studies.
Collapse
|
49
|
Crepél M, Salem N, Cosset J, Bossi A, Peiffert D, Pommier P, Nebout N, Guérif S, Delannes M, de Crevoisier R. Relapse after Prostate Brachytherapy: Patterns of Failure and Salvage Treatment. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
50
|
Ducassou A, David I, Bonnet J, Delannes M. Étude rétrospective du contrôle local et du résultat cosmétique de 147 carcinomes de la face après curiethérapie interstitielle. Cancer Radiother 2009. [DOI: 10.1016/j.canrad.2009.08.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|